Catherine Schulte

Apr 29, 2026

Catherine Schulte rated QGEN as Outperform on Apr 29, 2026, setting a price target of 43. Shares have remained stable near 34.02, leaving the 43 target still in play.

Apr 24, 2026

On Apr 24, 2026, TMO was given a Outperform rating by Catherine Schulte, with a target price of 639. The stock traded sideways with a % move, keeping the bullish thesis unresolved.

Apr 22, 2026

DHR received a Outperform rating from Catherine Schulte on Apr 22, 2026, aiming for 245. Price action was muted, as shares hovered around 178.98 despite the bullish outlook.

Feb 27, 2026

On Feb 27, 2026, Catherine Schulte published a Outperform outlook on CAI, with a target of 28. Market action contradicted the Buy thesis, as shares slipped to 18.44.

Feb 20, 2026

Catherine Schulte on Feb 20, 2026 assigned GRAL a Outperform rating, with a price target of 113. The recommendation remains pending validation as shares consolidate around 52.2.

Feb 17, 2026

On Feb 17, 2026, Catherine Schulte reaffirmed GH with a Outperform rating, targeting 120. Shares slid 22.43% despite the recommendation, highlighting downside risks.

Feb 17, 2026

TEM was rated Outperform by Catherine Schulte on Feb 17, 2026, with a price objective of 59. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

Nov 25, 2025

On Nov 25, 2025, Catherine Schulte initiated coverage on A with a Outperform rating and target of 165. The Buy call has yet to be validated as shares remain 50.13 away from the target.

Nov 04, 2025

Catherine Schulte issued a Outperform recommendation for EXAS on Nov 04, 2025, price target set at 88. Investors following the Buy call captured upside momentum, with shares now at 104.91.

Oct 24, 2025

On Oct 24, 2025, AVTR was evaluated by Catherine Schulte, who gave a Outperform rating and target of 17. Investors saw limited payoff as shares fell short of the 17 target.